The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils
Open accessAbstract
The aggregation of alpha-synuclein has been implicated as a critical step in the development of Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopaminergic neurons from the substantia nigra; currently, no cure exists. Baicalein is a flavonoid with antioxidant properties; upon oxidation, it forms several products including quinones. We show here that low micromolar concentrations of baicalein, and especially its oxidized forms, inhibit the formation of alpha-synuclein fibrils. In addition, existing fibrils of alpha-synuclein are disaggregated by baicalein. The product of the inhibition reaction is predominantly a soluble oligomer of alpha-synuclein, in which the protein molecules have been covalently modified by baicalein quinone to form a Schiff base with a lysine side chain in alpha-synuclein. The binding of baicalein was abolished by conversion of the Tyr residues into Phe, demonstrating that Tyr is involved in the interaction of alpha-synuclein with baicalein. In disaggregation baicalein causes fragmentation throughout the length of the fibril. These observations suggest that baicalein and similar compounds may have potential as therapeutic leads in combating Parkinson's disease and that diets rich in flavonoids may be effective in preventing the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
A Spectrophotometric Investigation of the Interaction of Iodine with Aromatic Hydrocarbons
Benesi, H. A., & Hildebrand, J. H. (1949) · Journal of the American Chemical Society · doi:10.1021/ja01176a030 · Cited by 8,004
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465
Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T
Naiki, H., Higuchi, K., Hosokawa, M., & Takeda, T. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90046-8 · Cited by 1,223
Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V. N., & Fink, A. L. (2001) · Biochemistry · doi:10.1021/bi002555c · Cited by 1,175
Self-citationOxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
Joseph, J. A., Shukitt-Hale, B., Denisova, N. A., Bielinski, D., Martin, A., McEwen, J. J., & Bickford, P. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-18-08114.1999 · Cited by 980
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., & Lansbury, P. T. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00735-0 · Cited by 805
Pathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693
Cited by
Endoplasmic reticulum stress signalling-from basic mechanisms to clinical applications
Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., Luís, A., McCarthy, N., Montibeller, L., More, S., et al. (2019) · The FEBS Journal · doi:10.1111/febs.14608 · Cited by 1,034
EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity
Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., & Wanker, E. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910723107 · Cited by 1,011
Porat, Y., Abramowitz, A., & Gazit, E. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00318.x · Cited by 989
Necula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J. W., & Uversky, V. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 657
Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins
Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S.-I., Iwatsubo, T., Goedert, M., & Hasegawa, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408714200 · Cited by 540
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 499
Recent Advances in the Genetics of Parkinson's Disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101440 · Cited by 437
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Lashuel, H. A., & Lansbury, P. T. (2006) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004422 · Cited by 400
Polymorphism in the intermediates and products of amyloid assembly
Kodali, R., & Wetzel, R. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.01.007 · Cited by 376
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B. H., & Riederer, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 352
The Oxidation State of DJ-1 Regulates its Chaperone Activity Toward α-Synuclein
Zhou, W., Zhu, M., Wilson, M. A., Petsko, G. A., & Fink, A. L. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.12.030 · Cited by 350
Self-citationHabitual intake of dietary flavonoids and risk of Parkinson disease
Gao, X., Cassidy, A., Schwarzschild, M. A., Rimm, E. B., & Ascherio, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31824f7fc4 · Cited by 332
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Ono, K., & Yamada, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03707.x · Cited by 320
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Curcumin Modulates α-Synuclein Aggregation and Toxicity
Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., & Maji, S. K. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001203 · Cited by 307
Biological Implications of Lipid Oxidation Products
Vieira, S. A., Zhang, G., & Decker, E. A. (2017) · Journal of the American Oil Chemists' Society · doi:10.1007/s11746-017-2958-2 · Cited by 280
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds
Caruana, M., Högen, T., Levin, J., Hillmer, A., Giese, A., & Vassallo, N. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.046 · Cited by 273
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
Small-molecule aggregates inhibit amyloid polymerization
Feng, B. Y., Toyama, B. H., Wille, H., Colby, D. W., Collins, S. R., May, B. C. H., Prusiner, S. B., Weissman, J., & Shoichet, B. K. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.65 · Cited by 260
Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
Intrinsically disordered proteins and biomolecular condensates as drug targets
Biesaga, M., Frigolé-Vivas, M., & Salvatella, X. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.009 · Cited by 115
Targeting the unfolded protein response for disease intervention.
Rivas, A., Vidal, R. L., & Hetz, C. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1053869 · Cited by 62
Murakami, K., & Irie, K. (2019) · Molecules · doi:10.3390/molecules24112125 · Cited by 31
“Fink and coworkers first identified the possible significance of the o-quinone moiety of baicalein having the catechol structure in the A-ring for suppressing α-synuclein aggregation, which is responsible for Parkinson’s disease [41].”
Background
Metadata
- Authors
- Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., & Fink, A. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 279
- Issue
- 26
- Pages
- 26846-26857
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2160643911
- Cited by
- 473
- References
- 40
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.